10 Nov, 2021

Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®

Spago Nanomedical AB today announced it has signed an agreement with the global CRO Cmed Group Limited for the development of the first clinical study with the company’s therapy project Tumorad.

The aim of the clinical trial will be to assess safety and demonstrate proof-of-concept in cancer patients. The first preparatory phase, that is now in progress, includes the design of the clinical study protocol and compilation of material for the clinical trial application, consultation and advice with relevant regulatory agencies, and identification of suitable clinical sites for the study.

”The agreement with Cmed marks an important step in the preparations of the clinical development of Tumorad. The study design is emerging, and I look forward for us to initiate the first clinical trial with our candidate drug SN201 in cancer patients in 2022”, said Mats Hansen, CEO of Spago Nanomedical.

”We look forward to contribute to the development of Tumorad, which is an exciting new product for the treatment of aggressive cancer”, said Stephanie Langouet, COO of Cmed.

The regulatory preclinical dosimetry and toxicology studies with SN201 are progressing well and preparations for GMP production are ongoing with an external contract manufacturing organization.